Drug Discovery World
MAY 30, 2024
A new research paper has validated the mechanism of action of the Atrogi’s first-in-class, small molecule, ATR-127, in combating obesity and metabolic complications. We are now advancing our next generation small molecules for the treatment of obesity to IND preparatory studies in H1 next year and expect to enter the clinic in 2026.”
Drug Hunter
APRIL 24, 2023
The new laws include Medicare negotiation and includes a provision that disproportionately affects small molecules which have triggered reactions throughout the industry from the extreme of “this is the end of small molecule drug discovery as we know it” to “this may not cause permanent damage.”
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
JANUARY 24, 2024
DDW’s Megan Thomas caught up with Wigerinck to learn more about his work with small molecules for fibrosis research. MT: Your appointment comes as Fibrocor seeks to advance two drug candidates – exquisitely specific kinase inhibitor small molecules (FIB992 and FIB991) for rare indications into the clinic.
Drug Target Review
JULY 4, 2023
These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. The global ADC market is expected to continue this steep upward trajectory and is anticipated to exceed $16 Billion by 2026. 3D rendering of Antibody Drug Conjugate Molecules.
LifeSciVC
APRIL 2, 2024
We experienced strong enthusiasm for small molecule research in the investor community. We have milestones on the horizon, and we want investors to stay close to the Sionna story even if we don’t need capital until 2026. The last takeaway is just how much the experience around us made a difference.
The Pharma Data
MAY 2, 2023
Starting in 2026, this facility will develop manufacturing processes for active pharmaceutical ingredients and produce drugs for use in clinical trial phases. Biopharmaceuticals and small molecules each account for approximately half of the company’s research pipeline.
Drug Target Review
JANUARY 4, 2024
This is in part due to a complex manufacturing process, which is harder to control than those used for other modalities (such as small molecules and monoclonal antibodies). Then it’s on to dosing and administration studies in animals, pivotal toxicology studies, and, following a successful funding round, first-in-human studies in 2026.
Expert insights. Personalized for you.
147 
Let's personalize your content